[1] 何长伦. 慢性乙型肝炎口服抗病毒药物评价[J]. 肝脏,2008,13(2):154-157. [2] 中华医学会肝病学分会和感染病学分会. 慢性乙型肝炎防治指南[J]. 实用肝脏病杂志,2006,9(1):8-18. [3] HOOF JH,DOO E, LIANG TJ,et al. Management of hepatitis B:Summary of a clinical research workshop[J]. Hepatology,2007,45(4):1056-1075. [4] LAI C L,LEUNG N,TEO EK,et al. A-1-year trial of telbivudine,lamivudine and the combination in patients with hepatitis B E antigen-positive chronic hepatitis B[J]. Gastroenterology,2005,129(4):528-536. [5] YUEN MF,LAI CL. Telbivudine,an upcoming agent for chronic hepatitis B[J]. Expert Rev Infeet Ther,2005,3(3):489-494. [6] 王常青,钱凯先,王勇. Tα1治疗肝病的作用机制与临床应用研究进展[J]. 国际流行病学传染病学杂志,2006,33(2):124-127. [7] SUGAHARA SI,CHIDA T,YAMAGIWA S,et al. Thymosin-alpha I increases intrahepatic NK T cells and CTLs in patients wite chronic hepatitis B[J]. Hepatol Res,2002,24(4):346-354. [8] SIOGREN MH. Thymalfasin:an immune system enhancer for the treatment of liver disease[J]. Gastroenterology,2004,9(1):69-72. [9] ARASE Y,TSUBOTA A,SUZUKI Y,et al. A pilot study of thymosin alpha I therapy for chronic hepatitis B patients[J]. Intern Med,2003,42(10):941-946. [10] 吴福全,俞洪林,黄绍坤. 拉米夫定联合胸腺肽α1治疗慢性乙型肝炎的疗效观察[J]. 中华肝脏病杂志,2002,10(3):218-219. [11] 符静,陈良. 拉米夫定联合胸腺肽治疗慢性乙型肝炎的疗效[J]. 中华传染病杂志,2003,21(4):287-288. [12] 陆卫英,孙莲娜,杜秀萍,等. 拉米夫定联合α1胸腺肽治疗慢性乙型肝炎的疗效观察[J]. 实用肝脏病杂志,2007,10(6):344-345. |